“The future of healthcare isn’t about choosing between pharmaceuticals and natural health products; it’s about combining scientific rigor with innovative thinking.”
That philosophy underpins the conversation with Sara Tylosky, CEO of Farmacon, in the latest episode of the Life Sciences – In Focus podcast.
Drawing on decades of experience in pharmaceuticals, clinical research, patient recruitment, and international healthcare, Sara shares why the lines between traditional pharmaceuticals and nutraceuticals are becoming increasingly blurred. From AI-driven clinical development to the growing importance of Latin America in global research, she offers a compelling vision of where the life sciences industry is headed.
From Pharma Leadership to Global Healthcare Innovation
Sara’s career has been anything but conventional. After building a successful career in pharmaceutical sales, marketing, and leadership, including roles at GSK, she stepped away from the industry to establish a nonprofit supporting education in rural Mexico. That experience broadened her perspective on healthcare, access, and global collaboration before leading her back into clinical research.
Today, as CEO of Farmacon, Sara leads an organization that acts as a strategic partner for pharmaceutical and biotechnology companies. Rather than operating as a traditional CRO, Farmacon provides modular clinical development and operational support, helping organizations solve complex challenges in patient recruitment, clinical trial operations, and market expansion.
Throughout the discussion, Sara returns to a common theme: improving healthcare ultimately means helping patients access better treatments more efficiently.
The Convergence of Pharmaceuticals and Nutraceuticals
One of the most fascinating topics explored during the episode is the increasing convergence between pharmaceuticals and nutraceuticals.
According to Sara, consumers are demanding stronger scientific evidence behind health products, while companies developing nutraceuticals are increasingly investing in rigorous clinical trials traditionally associated with pharmaceutical development.
As regulatory expectations continue to evolve globally, the distinction between supplements, biologics, pharmaceuticals, and other healthcare products is becoming less defined. Companies are recognizing that robust clinical evidence is no longer optional; it is becoming essential for building trust with regulators, healthcare professionals, and consumers alike.
Sara highlights emerging companies developing regenerative stem cell therapies and microbiome-based treatments as examples of how naturally derived products are entering mainstream clinical development while adhering to pharmaceutical-grade research standards.
Artificial Intelligence is Accelerating Innovation
No discussion about the future of life sciences would be complete without addressing artificial intelligence.
Sara explains that AI is already transforming drug discovery, clinical trial design, analytical testing, and manufacturing optimization. Rather than replacing scientific expertise, AI is reducing development timelines and lowering the cost of generating high-quality clinical evidence.
However, she also acknowledges that adoption remains uneven across the industry. While larger pharmaceutical organizations have invested heavily in governance, cybersecurity, and AI policies, many smaller companies continue to take a more cautious approach.
For Sara, successful AI implementation depends not only on technology but also on responsible governance and maintaining the confidence of clients operating in highly regulated environments.
Why Latin America Deserves Greater Attention
Another key theme throughout the conversation is Latin America’s growing role in global clinical research.
Sara argues that the region represents one of the most significant opportunities for sponsors seeking efficient, high-quality clinical trials. With more than 660 million people, increasingly sophisticated regulatory agencies, experienced research centers, and treatment-naïve patient populations, Latin America offers considerable advantages for both pharmaceutical and nutraceutical development.
Drawing on years of experience working throughout the region, she explains that success depends on understanding local regulatory environments, cultural nuances, and partnering with organizations that possess deep regional expertise.
She also reflects on Farmacon’s involvement in recruiting approximately 9,000 participants for a COVID-19 plant-based vaccine program, an experience that reinforced her belief in developing more naturally derived healthcare solutions supported by rigorous clinical science.
Collaboration Will Define the Future
As the conversation concludes, Sara returns to the importance of collaboration across the healthcare ecosystem. Whether developing innovative nutraceuticals, expanding global clinical trials, navigating regulatory pathways, or integrating AI into research, she believes organizations will achieve the greatest success by combining scientific excellence with strategic partnerships.
The healthcare landscape is evolving rapidly, and Sara’s message is clear: innovation requires collaboration, evidence, and a willingness to challenge traditional boundaries between disciplines.
As she puts it, the goal remains simple, even if achieving it is not: to bring better health solutions to patients around the world.
About Life Sciences – In Focus
Life Sciences – In Focus Podcast by Visatatec, a fascinating conversation with global life sciences experts. The show has multiple hosts and topics. Follow Life Sciences – In Focus on Spotify for all the latest episodes, or subscribe to the show on YouTube and Apple podcasts. Life Sciences – In Focus is available on many other podcast platforms. To learn more about the podcast, please visit https://vistatec.com/life-sciences-division.
About Vistatec
We have been helping some of the world’s most iconic brands to optimize their global commercial potential since 1997. Vistatec is one of the world’s leading global content solutions providers. HQ in Dublin, Ireland, with offices in Mountain View, California, USA. To learn more about Vistatec, please visit https://www.vistatec.com